JP2017517551A - メロキシカムの新規製剤 - Google Patents

メロキシカムの新規製剤 Download PDF

Info

Publication number
JP2017517551A
JP2017517551A JP2016572654A JP2016572654A JP2017517551A JP 2017517551 A JP2017517551 A JP 2017517551A JP 2016572654 A JP2016572654 A JP 2016572654A JP 2016572654 A JP2016572654 A JP 2016572654A JP 2017517551 A JP2017517551 A JP 2017517551A
Authority
JP
Japan
Prior art keywords
meloxicam
less
minutes
dosage form
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016572654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517551A5 (enExample
Inventor
ウィリアム・エイチ・ボッシュ
Original Assignee
イシューティカ ピーティーワイ リミテッド
イシューティカ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54768708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017517551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イシューティカ ピーティーワイ リミテッド, イシューティカ ピーティーワイ リミテッド filed Critical イシューティカ ピーティーワイ リミテッド
Publication of JP2017517551A publication Critical patent/JP2017517551A/ja
Publication of JP2017517551A5 publication Critical patent/JP2017517551A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016572654A 2014-06-09 2015-06-09 メロキシカムの新規製剤 Pending JP2017517551A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009860P 2014-06-09 2014-06-09
US62/009,860 2014-06-09
US14/675,410 US9526734B2 (en) 2014-06-09 2015-03-31 Formulation of meloxicam
US14/675,410 2015-03-31
PCT/US2015/034923 WO2015191595A1 (en) 2014-06-09 2015-06-09 A novel formulation of meloxicam

Publications (2)

Publication Number Publication Date
JP2017517551A true JP2017517551A (ja) 2017-06-29
JP2017517551A5 JP2017517551A5 (enExample) 2018-07-19

Family

ID=54768708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572654A Pending JP2017517551A (ja) 2014-06-09 2015-06-09 メロキシカムの新規製剤

Country Status (18)

Country Link
US (8) US9526734B2 (enExample)
EP (1) EP3151835A4 (enExample)
JP (1) JP2017517551A (enExample)
KR (1) KR20170017915A (enExample)
CN (1) CN107073010A (enExample)
AP (1) AP2016009611A0 (enExample)
AU (1) AU2015274838B2 (enExample)
BR (1) BR112016027435A2 (enExample)
CA (1) CA2951383A1 (enExample)
EA (1) EA201692392A1 (enExample)
IL (1) IL248699A0 (enExample)
MA (1) MA39443A1 (enExample)
MX (1) MX2016016212A (enExample)
NZ (1) NZ726610A (enExample)
PH (1) PH12016502336A1 (enExample)
SG (1) SG11201610179QA (enExample)
WO (1) WO2015191595A1 (enExample)
ZA (1) ZA201700022B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021008412A (ja) * 2019-06-28 2021-01-28 エスエス製薬株式会社 メロキシカム含有造粒物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN108949699B (zh) 2018-08-03 2020-09-04 江南大学 一种分泌美洛昔康单克隆抗体的杂交瘤细胞株及其应用
CN111346097B (zh) * 2018-12-22 2023-03-24 江苏先声药业有限公司 一种组合物及其制备方法
WO2020219406A1 (en) * 2019-04-22 2020-10-29 Mylan Specialty L.P. Meloxicam co-crystal compositions
US20210093642A1 (en) * 2019-09-26 2021-04-01 Cadila Healthcare Limited STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
WO2021224815A1 (en) * 2020-05-06 2021-11-11 Cadila Healthcare Limited Stable aqueous parenteral solutions of nonsteroidal anti-inflammatory drug (nsaid)
US20250352552A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
US12648912B2 (en) * 2020-11-06 2026-06-09 Mylan Laboratories Limited Pharmaceutical composition comprising meloxicam
CN115844820B (zh) * 2022-11-23 2023-08-29 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法
US12697341B1 (en) 2025-05-07 2026-08-04 Viatris Inc. Methods of using meloxicam for pain treatment and management

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
WO2010121325A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of meloxicam
US20120168335A1 (en) * 2009-08-31 2012-07-05 David Allen Burns Fast Disintegrating Compositions of Meloxicam, Processes for Preparation, and Use to Treat Arthritis and/or Pain

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172546A (en) 1961-05-19 1965-03-09 Union Carbide Corp Size reduction of biological substances
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IT1082518B (it) 1977-01-25 1985-05-21 Fiat Spa Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
IL112746A (en) 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
KR20010023256A (ko) 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1066825A1 (en) 1999-06-17 2001-01-10 The Procter & Gamble Company An anti-microbial body care product
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1341521B1 (en) 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
EP2283817B1 (en) 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
WO2003000228A2 (en) 2001-06-22 2003-01-03 Elan Pharma International Ltd. Method for high through put screening using a small scale mill or microfluidics
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US6825161B2 (en) 2002-04-26 2004-11-30 Salvona Llc Multi component controlled delivery system for soap bars
AU2003276688A1 (en) 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1832583A1 (en) 2002-09-30 2007-09-12 A/S GEA Farmaceutisk Fabrik Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
US20040173696A1 (en) 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050163839A1 (en) 2003-01-29 2005-07-28 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
PT1638527E (pt) 2003-06-27 2007-02-28 Bioprogress Spa Produto compósito obtido por co-trituração de um princípio activo com um copolímero de n-vinil-2-pirrolidona/acetato de vinilo
WO2005004915A2 (en) 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
ES2318330T3 (es) 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
AU2004277750B9 (en) 2003-10-01 2010-07-15 Debio Recherche Pharmaceutique S.A. Device and method for making particles
WO2005044234A2 (en) 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1755559A1 (en) 2004-03-08 2007-02-28 Spiridon Spireas Bioavailable solid dosage forms of metaxalone
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
WO2006009419A1 (es) 2004-07-19 2006-01-26 Luis Cordova Boone Neumáticos con doble banda de rodamiento
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (en) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Pharmaceutical dosage form comprising meloxicam
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2858733C (en) 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
WO2006116596A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
SG166115A1 (en) * 2005-09-30 2010-11-29 Boehringer Ingelheim Vetmed Pharmaceutical preparation containing meloxicam
US20080292584A1 (en) 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2007070843A2 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
CA2631494A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
WO2007074477A2 (en) 2005-12-29 2007-07-05 Dabur Pharma Limited Metaxalone polymorphs
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
JP2009541360A (ja) 2006-06-23 2009-11-26 エラン・ファルマ・インターナショナル・リミテッド ナノ粒子状メロキシカムおよび制御放出ヒドロコドンを含む組成物
NZ573823A (en) 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
CN100386312C (zh) 2006-07-18 2008-05-07 上海世景国际贸易有限公司 2，4-二氨基苯磺酸及其盐的合成方法
KR20090027734A (ko) 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TWI405590B (zh) 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
RU2010153904A (ru) 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
AP2015008965A0 (en) 2009-04-24 2016-01-31 Iceutica Pty Ltd Method for improving the dissolutionprofile of a biologically active material
NZ595985A (en) 2009-04-24 2014-07-25 Iceutica Pty Ltd A novel formulation of naproxen
KR20160148041A (ko) 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
CA2759123C (en) 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions of diclofenac acid with improved dissolution
MX360019B (es) 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
MX356518B (es) 2009-04-24 2018-05-31 Iceutica Pty Ltd Producción de nanopartículas encapsuladas en fracciones de alto volumen.
BR112016001395A8 (pt) 2013-07-22 2020-01-14 Iceutica Inc forma de dosagem unitária oral sólida de metaxalona
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
JP2007505154A (ja) * 2003-03-03 2007-03-08 エラン ファーマ インターナショナル リミテッド ナノ粒子のメロキシカム製剤
WO2010121325A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of meloxicam
US20120141548A1 (en) * 2009-04-24 2012-06-07 Fundacionuniversidad Del Norte Novel formulation of meloxicam
JP2012524721A (ja) * 2009-04-24 2012-10-18 イシューティカ ピーティーワイ リミテッド メロキシカムの新規製剤
US20120168335A1 (en) * 2009-08-31 2012-07-05 David Allen Burns Fast Disintegrating Compositions of Meloxicam, Processes for Preparation, and Use to Treat Arthritis and/or Pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
メロキシカム錠５ＭＧ／１０ＭＧ「サワイ」 医薬品インタビューフォーム, 2012.03, P. 1-31, JPN6019005741, ISSN: 0004313646 *
メロキシカム錠５ＭＧ／１０ＭＧ「トーワ」 医薬品インタビューフォーム, 2011.08, P. 1-36, JPN6019005742, ISSN: 0004313647 *
メロキシカム錠５ＭＧ「日医工」 メロキシカム錠１０ＭＧ「日医工」 添付文書, 2011.08, P. 1-4, JPN6019005743, ISSN: 0004313648 *
モービック錠５ＭＧ モービック錠１０ＭＧ 添付文書, 2011.08, P. 1-4, JPN6019005744, ISSN: 0004313649 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021008412A (ja) * 2019-06-28 2021-01-28 エスエス製薬株式会社 メロキシカム含有造粒物
JP7348703B2 (ja) 2019-06-28 2023-09-21 エスエス製薬株式会社 メロキシカム含有造粒物

Also Published As

Publication number Publication date
CN107073010A (zh) 2017-08-18
WO2015191595A1 (en) 2015-12-17
ZA201700022B (en) 2018-05-24
MA39443A1 (fr) 2017-10-31
US20180050042A1 (en) 2018-02-22
US20150352122A1 (en) 2015-12-10
AP2016009611A0 (en) 2016-12-31
US9808468B2 (en) 2017-11-07
BR112016027435A2 (pt) 2017-10-17
US9526734B2 (en) 2016-12-27
NZ726610A (en) 2020-05-29
EA201692392A1 (ru) 2017-03-31
PH12016502336A1 (en) 2017-02-13
US9649318B2 (en) 2017-05-16
EP3151835A4 (en) 2018-01-10
US20200085835A1 (en) 2020-03-19
US20160101110A1 (en) 2016-04-14
CA2951383A1 (en) 2015-12-17
EP3151835A1 (en) 2017-04-12
US20250235461A1 (en) 2025-07-24
US20210213028A1 (en) 2021-07-15
MX2016016212A (es) 2017-02-23
SG11201610179QA (en) 2017-01-27
IL248699A0 (en) 2017-01-31
US20170246178A1 (en) 2017-08-31
KR20170017915A (ko) 2017-02-15
AU2015274838B2 (en) 2019-07-04
US20230414630A1 (en) 2023-12-28
AU2015274838A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
US9808468B2 (en) Formulation of meloxicam
JP6239709B2 (ja) インドメタシンの新規製剤
JP6154846B2 (ja) ジクロフェナクの新規製剤
JP6040026B2 (ja) メロキシカムの新規製剤
BRPI1014278B1 (pt) método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma
US20250084043A1 (en) Formulation of metaxalone
HK1242624A1 (en) A novel formulation of meloxicam
OA19000A (en) A novel formulation of meloxicam
HK1233538A1 (zh) 双氯芬酸的新剂型
HK1232808A1 (en) A novel formulation of diclofenac
BRPI1014272B1 (pt) Composição e composição farmacêutica que compreende partículas de ácido diclofenaco

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180607

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200728